This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PRT060128, PRT128
Description: PRT060128 is a reversible IV and oral ADP receptor antagonist in clinical development. Inhibiting the ADP receptor on platelets prevents platelet thrombosis and subsequent heart attacks. Portola believes that PRT060128 may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting.
The half-life of PRT060128 is 12 hours. There is no major CYP metabolism. Clearance is 50% renal, 50% hepatic, and 10% is metabolized to a pharmacologically inactive metabolite.
Deal Structure: PRT060128 was originally developed by Portola.
In February 2009, Novartis announced that it gained the exclusive worldwide rights to elinogrel (PRT060128). Novartis will make an upfront payment of USD 75 million to Portola for the exclusive worldwide rights to elinogrel. Novartis will share with Portola the costs of the ongoing Phase II trial, but will have responsibility for Phase III clinical development, manufacturing and commercialization. Portola will also be eligible for additional payments based on achieving defined development and commercialization milestones and is also eligible to receive royalties on future sales. In addition, Portola has an option to co-promote elinogrel in the US limited to hospitals and specialty markets and an option to co-fund Phase III clinical trials and other development activities in return for additional royalties.
Partners: Portola Pharmaceuticals, Inc.
Additional information available to subscribers only: